COPD Patients Experience Lung Function Improvement From Anoro Ellipta Compared to Tiotropium

COPD Patients Experience Lung Function Improvement From Anoro Ellipta Compared to Tiotropium

Lung FunctionResults from a new clinical trial on Chronic Obstructive Pulmonary Disease were recently published in Respiratory Medicine in a study entitled “Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.” The findings outlined in the trial may suggest a new therapeutic option for patients with the disease, as use of Anoro Ellipta led to improved lung function.

Chronic Obstructive Pulmonary Disease (COPD) is a lung disease characterized by airflow obstruction leading to difficulties in breathing. In the study, the efficacy and safety were assessed for administering once-a-day, UMEC/VI 62.5/25mcg inhalation powder in the Ellipta® inhaler when compared to tiotropium 18mcg administered once-a-day in the HandiHaler® inhaler. The study was performed over 24 weeks and included 905 patients with COPD from different centers.

The study’s primary endpoint measured lung function by measuring forced expiratory volume in one-second (FEV1) at the end of the treatment. The secondary endpoint determined lung function through weighted mean FEV1 0 – 6 hour in the same period.

Treatment with UMEC/VI 62.5/25mcg in Ellipta® inhaler resulted in significant improvements both to primary and secondary study endpoints when compared to treatment with tiotropium 18mcg in HandiHaler® inhaler.

[adrotate group=”3″]

Side effects for both treatments, UMEC/VI 62.5/25 and tiotropium 18mcg, most commonly included headache, nasopharyngitis, cough, and back pain.

Darrell Baker, SVP and Head, Global Respiratory Franchise, GSK commented, “We are pleased to announce the publication of these important data comparing Anoro Ellipta with tiotropium. These results support the lung function benefit of Anoro Ellipta in the treatment of appropriate patients with COPD. We hope the publication will inform physicians as they consider which treatment option is best to meet their individual patient’s needs.”

Michael W. Aguiar, President and Chief Executive Officer of Theravance, noted, “We believe the results from this positive study will provide physicians with additional useful data regarding the potential benefits of Anoro Ellipta as a treatment option for appropriate patients with COPD.”

Leave a Comment

Your email address will not be published. Required fields are marked *